Aethlon Medical to Present at Today's Southern California Investor Conference
SAN DIEGO, Aug. 18 Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced that it will present at today's 14th Annual Southern California Investor Conference being held at the Island Hotel in Newport Beach, California. The conference is hosted by California Equity Research and highlights growth companies located in the region, including world-recognized life science, technology, media, and real estate/financial organizations. Aethlon Medical Chairman and CEO, Jim Joyce will present at 2:15 p.m. Pacific time followed by a break-out session and one-on-one meetings. For more information on the Southern California Investor Conference, please visit the conference website at www.californiastocks.com or call the conference desk at (858) 829-8688.
About Aethlon Medical
Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier(R) represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier(R) seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.
Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, the capability of the Hemopurifier(R) to reduce viral loads and other disease conditions, the Company's ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company's ability to manufacture its products and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.
Contacts: Jon Cunningham RedChip Companies Inc. (407) 644-4256 (407) 491-4498 -cell www.redchip.com Jon@redchip.com Jim Joyce Chairman, CEO 858.459.7800 x301 firstname.lastname@example.org Jim Frakes Senior VP Finance 858.459.7800 x300 email@example.com
SOURCE Aethlon Medical, Inc.
You May Also Like